Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $11.63 billion. The enterprise value is $11.84 billion.
| Market Cap | 11.63B |
| Enterprise Value | 11.84B |
Important Dates
The next estimated earnings date is Thursday, January 30, 2025, before market open.
| Earnings Date | Jan 30, 2025 |
| Ex-Dividend Date | Nov 8, 2024 |
Share Statistics
Bio-Techne has 158.89 million shares outstanding. The number of shares has decreased by -0.76% in one year.
| Current Share Class | 158.89M |
| Shares Outstanding | 158.89M |
| Shares Change (YoY) | -0.76% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 1.06% |
| Owned by Institutions (%) | 98.78% |
| Float | 157.08M |
Valuation Ratios
The trailing PE ratio is 77.07 and the forward PE ratio is 37.97. Bio-Techne's PEG ratio is 3.41.
| PE Ratio | 77.07 |
| Forward PE | 37.97 |
| PS Ratio | 9.86 |
| Forward PS | 9.15 |
| PB Ratio | 5.44 |
| P/TBV Ratio | 17.35 |
| P/FCF Ratio | 47.45 |
| P/OCF Ratio | 38.31 |
| PEG Ratio | 3.41 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 38.37, with an EV/FCF ratio of 48.31.
| EV / Earnings | 78.56 |
| EV / Sales | 10.10 |
| EV / EBITDA | 38.37 |
| EV / EBIT | 48.55 |
| EV / FCF | 48.31 |
Financial Position
The company has a current ratio of 4.56, with a Debt / Equity ratio of 0.19.
| Current Ratio | 4.56 |
| Quick Ratio | 2.89 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 1.20 |
| Debt / FCF | 1.63 |
| Interest Coverage | 18.73 |
Financial Efficiency
Return on equity (ROE) is 7.29% and return on invested capital (ROIC) is 5.99%.
| Return on Equity (ROE) | 7.29% |
| Return on Assets (ROA) | 5.55% |
| Return on Capital (ROIC) | 5.99% |
| Revenue Per Employee | $384,126 |
| Profits Per Employee | $49,404 |
| Employee Count | 3,050 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, Bio-Techne has paid $25.59 million in taxes.
| Income Tax | 25.59M |
| Effective Tax Rate | 14.51% |
Stock Price Statistics
The stock price has decreased by -5.49% in the last 52 weeks. The beta is 1.27, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | -5.49% |
| 50-Day Moving Average | 73.29 |
| 200-Day Moving Average | 73.94 |
| Relative Strength Index (RSI) | 46.90 |
| Average Volume (20 Days) | 795,459 |
Short Selling Information
The latest short interest is 4.08 million, so 2.57% of the outstanding shares have been sold short.
| Short Interest | 4.08M |
| Short Previous Month | 3.53M |
| Short % of Shares Out | 2.57% |
| Short % of Float | 2.60% |
| Short Ratio (days to cover) | 3.52 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.17 billion and earned $150.68 million in profits. Earnings per share was $0.95.
| Revenue | 1.17B |
| Gross Profit | 773.19M |
| Operating Income | 243.81M |
| Pretax Income | 232.35M |
| Net Income | 150.68M |
| EBITDA | 308.52M |
| EBIT | 243.81M |
| Earnings Per Share (EPS) | $0.95 |
Balance Sheet
The company has $187.54 million in cash and $398.92 million in debt, giving a net cash position of -$211.38 million or -$1.33 per share.
| Cash & Cash Equivalents | 187.54M |
| Total Debt | 398.92M |
| Net Cash | -211.38M |
| Net Cash Per Share | -$1.33 |
| Equity (Book Value) | 2.14B |
| Book Value Per Share | 13.46 |
| Working Capital | 506.44M |
Cash Flow
In the last 12 months, operating cash flow was $303.49 million and capital expenditures -$58.46 million, giving a free cash flow of $245.03 million.
| Operating Cash Flow | 303.49M |
| Capital Expenditures | -58.46M |
| Free Cash Flow | 245.03M |
| FCF Per Share | $1.54 |
Margins
Gross margin is 65.99%, with operating and profit margins of 20.81% and 12.86%.
| Gross Margin | 65.99% |
| Operating Margin | 20.81% |
| Pretax Margin | 15.05% |
| Profit Margin | 12.86% |
| EBITDA Margin | 26.33% |
| EBIT Margin | 20.81% |
| FCF Margin | 20.91% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.44%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.44% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 33.70% |
| Buyback Yield | 0.76% |
| Shareholder Yield | 1.20% |
| Earnings Yield | 1.30% |
| FCF Yield | 2.11% |
Analyst Forecast
The average price target for Bio-Techne is $82.00, which is 12.07% higher than the current price. The consensus rating is "Buy".
| Price Target | $82.00 |
| Price Target Difference | 12.07% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 10.76% |
| EPS Growth Forecast (5Y) | 27.51% |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 12.97 and a Piotroski F-Score of 5.
| Altman Z-Score | 12.97 |
| Piotroski F-Score | 5 |